Auris Medical Holding AG (EARS) Earns Coverage Optimism Rating of 0.44

Media stories about Auris Medical Holding AG (NASDAQ:EARS) have trended positive on Friday, AlphaOne reports. The research group, a division of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Auris Medical Holding AG earned a media sentiment score of 0.44 on AlphaOne’s scale. AlphaOne also gave news articles about the biotechnology company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the company’s share price in the near term.

These are some of the news articles that may have impacted AlphaOne Sentiment Analysis’s analysis:

Several analysts recently issued reports on EARS shares. Needham & Company LLC reduced their price target on shares of Auris Medical Holding AG from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, March 14th. Roth Capital started coverage on shares of Auris Medical Holding AG in a research report on Thursday, April 13th. They set a “buy” rating and a $4.50 price target on the stock. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $5.44.

Shares of Auris Medical Holding AG (NASDAQ:EARS) traded up 2.328% during mid-day trading on Friday, reaching $0.655. 57,133 shares of the company’s stock were exchanged. Auris Medical Holding AG has a 52-week low of $0.62 and a 52-week high of $5.45. The firm’s market cap is $22.49 million. The company has a 50 day moving average price of $0.75 and a 200 day moving average price of $0.99.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.08. Analysts forecast that Auris Medical Holding AG will post ($0.57) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Auris Medical Holding AG (EARS) Earns Coverage Optimism Rating of 0.44” was originally reported by sleekmoney and is the sole property of of sleekmoney. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://sleekmoney.com/auris-medical-holding-ag-ears-earns-coverage-optimism-rating-of-0-44/1836722.html.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

5 Day Chart for NASDAQ:EARS

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/auris-medical-holding-ag-ears-earns-coverage-optimism-rating-of-0-44/1836722.html

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *